HomeCompareHILS vs JEPQ

HILS vs JEPQ: Dividend Comparison 2026

HILS yields 843.88% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HILS wins by $4363248.76M in total portfolio value
10 years
HILS
HILS
● Live price
843.88%
Share price
$0.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4363248.80M
Annual income
$3,538,417,394,347.70
Full HILS calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — HILS vs JEPQ

📍 HILS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHILSJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HILS + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HILS pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HILS
Annual income on $10K today (after 15% tax)
$71,729.96/yr
After 10yr DRIP, annual income (after tax)
$3,007,654,785,195.55/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, HILS beats the other by $3,007,654,783,365.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HILS + JEPQ for your $10,000?

HILS: 50%JEPQ: 50%
100% JEPQ50/50100% HILS
Portfolio after 10yr
$2181624.42M
Annual income
$1,769,208,698,250.14/yr
Blended yield
81.10%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HILS
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.3
Piotroski
2/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HILS buys
0
JEPQ buys
0
No recent congressional trades found for HILS or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHILSJEPQ
Forward yield843.88%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4363248.80M$44.8K
Annual income after 10y$3,538,417,394,347.70$2,152.59
Total dividends collected$4298592.53M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: HILS vs JEPQ ($10,000, DRIP)

YearHILS PortfolioHILS Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$95,088$84,388.19$11,930$1,110.39+$83.2KHILS
2$851,681$749,936.40$14,133$1,224.34+$837.5KHILS
3$7,188,859$6,277,560.82$16,632$1,340.46+$7.17MHILS
4$57,213,181$49,521,101.51$19,454$1,457.97+$57.19MHILS
5$429,552,802$368,334,698.45$22,626$1,576.08+$429.53MHILS
6$3,044,138,048$2,584,516,550.07$26,175$1,694.09+$3044.11MHILS
7$20,374,845,574$17,117,617,861.98$30,133$1,811.32+$20374.82MHILS
8$128,876,441,910$107,075,357,146.57$34,531$1,927.17+$128876.41MHILS
9$770,870,472,639$632,972,679,795.13$39,403$2,041.08+$770870.43MHILS
10$4,363,248,800,072$3,538,417,394,347.70$44,787$2,152.59+$4363248.76MHILS

HILS vs JEPQ: Complete Analysis 2026

HILSStock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Full HILS Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this HILS vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HILS vs SCHDHILS vs JEPIHILS vs OHILS vs KOHILS vs MAINHILS vs XYLDHILS vs QYLDHILS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.